Jobs
View more job listings or post a job
Denali Therapeutics Senior Scientist, DMPK
Denali Therapeutics Scientist, DMPK
ChemoCentryx Inc. Director or Senior Director, Toxicology
Catalent Pharma Solutions - San Diego Project Manager - Pharmaceutical development
Senior Scientist I (Pharmacology, PD/Efficacy) SUMMARY: Exelixis is seeking a highly self-motivated, interactive, and productive hands-on PhD scientist to join the Pharmacology team working towards discovery of anti-cancer agents for the treatment of targeted indicati
PTC Therapeutics BS-MS Associate, Biomarker Imaging
Jazz Pharmaceuticals Associate Director, Clinical Pharmacology
Jazz Pharmaceuticals Associate Director, Clinical Pharmacology
Chempartner Senior Scientist - Biologics
Gilead Sciences, Inc. Senior Research Scientist, Structural Chemistry
Post a job

Symposium

Covalent Inhibitor Drug Discovery & Development: Biology, Chemistry, PK, Safety and Case Studies (Jointly with Bay Area PKPD Network)


Speakers: Tom Baillie (Univ Washington), Jack Taunton (UCSF), Joachim Rudolph (Genentech), Dane Karr (Nurix), Zhengping Wang (Revolution Medicine), Shirin Kapur (ex-Onyx), Leah Schutt- (Genentech), Betty Chang (ex-Pharmacyclics)
Organizers: Xu (Richard) Zang, PhD (Genentech)
Date: 2019-02-07
Time: 8:45-17:00 Pacific Time
Registration fee: (USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location: Crowne Plaza, Foster City, CA
Major Sponsor: (1)Correlia Biosystems;(Major Sponsorship - Afternoon still open)
Vendor show vendors registered to date: (20)AIT Bioscience; Alturas Analytics; Averica Discovery Services; BioDuro; BioreclamationIVT; cgenetool; CMIC Inc.; Cytovier LLC; Intertek; MagArray; MedChemExpress; Medpace; MicroConstants; MRIGlobal; Nucleo Life Sciences; Q2 Solutions; Sekisui XenoTech, LLC; Selvita Inc.; Seventh Wave; WuXi AppTec
Registration: http://www.PBSS.org
Registration deadline:2019-02-04  (it will close sooner if the seating cap is reached)

About the Topic

In recent years, there has been a renewed interest in drug development of covalent inhibitors.  Several of these inhibitors have been approved by the FDA and EMA and more covalent inhibitors are in early and late stage development.  Covalent inhibitors can have superior affinity towards target proteins compared to their non-covalent counterparts, potentially resulting in improved therapeutic benefit.  This symposium will cover a wide range topics pertaining to covalent inhibitors discovery and development

Key Topics:

  • Targeted Covalent Inhibitors for Drug Design – Tom Baillie (UW)
  • Kinetic selectivity with lysine-targeted kinase inhibitors – Jack Taunton (UCSF)
  • Covalent modification in drug discovery - a chemist's perspective – Joachim Rudolph (Genentech)
  • Preclinical challenges for reversible covalent inhibitors – Dane Karr (Principia)
  • Development of covalent proteosome inhibitors: DMPK and clinical pharmacology perspectives – Zhengping Wang (Revolution Medicine)
  • Benchmark for Selective Sustained Proteasome Inhibition – Shirin Kapur (Cortexyme)
  • Safety Considerations for Covalent Inhibitors - Leah Schutt- (Genentech)
  • From bench to bedside: The story of a first-in-class covalent BTK inhibitor ibrutinib– Betty Chang


Agenda:

8:45-8:55           Welcome and overview - Richard Zang / Shichang Miao

8:55-9:40           Targeted Covalent Inhibitors for Drug Design - Tom Baillie

9:40-10:25         Kinetic selectivity with lysine-targeted kinase inhibitors - Jack Taunton

10:25-10:35       Major Sponsor's Presentation

10:35-10:50       Break

10:50-11:35       Covalent modification in drug discovery - a chemist's perspective - Joachim Rudolph

11:35-12:20       Safety Considerations for Covalent Inhibitors - Leah Schutt

12:20-13:20       Lunch

13:20-14:05       Preclinical challenges for reversible covalent inhibitors - Dane Karr

14:05-14:50       From bench to beside:  The story of a first-in-class covalent BTK inhibitor ibrutinib - Betty Chang

14:50-15:00       Major Sponsor's Presentation

15:00-15:15       Break

15:15-16:00       Benchmark for Selective Sustained Proteasome Inhibition - Shirin Kapur

16:00-16:45       Development of covalent proteasome inhibitors: DMPK and clinical pharmacology perspectives - Zhengping Wang

16:45-17:15       Panel Discussion


2021-02-16, [Free Online Symposium] Oxbryta® (Voxelotor) tablets for Sickle Cell Disease: The R&D Journey and Lessons Learned (jointly by PBSS and CLSA)
2021-03-09, [Free Online Workshop] Metabolite Identification: Strategies, Techniques and Case Studies
2021-03-23, [Free Online Symposium] Cardiac Safety from Preclinical to the Clinic: Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks
2021-04-26, [Free Online Symposium] Highlights from 2020's FDA New Drug Approvals (jointly by PBSS and CLSA)
2021-07-29, [Free Online Symposium] Development of Inhalation Therapeutics (jointly by AAPS-BADG / PBSS / Genentech)
©Pharmaceutical & BioScience Society, International; Last Modified: 1/26/2021; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Hypha Discovery Limited Experts in drug metabolite synthesis & purification including CYP, AOX, FMO metabolites as well as O-, N-, acyl- glucuronides, glycosides & sulfates.
Eurofins Discovery On-Demand Take a coffee break with Discovery On-Demand! Mini webinars for remote learning avail 24/7 to accelerate your drug discovery program with confidence.
Eurofins Discovery Biomarker Services Cytokine Storm Assay for immunosafety profiles, STING Assay for in-depth evaluation of immune impacts; 360+ multiparameter flow cytometry capabilities
BioPharmEquip Isolators, PCM-based Smart Temp-Controlled Packaging, Viable Air Sampler, -80C Biorepository Walk-Ins, Stability Chambers, Single-Use Containment
Eurofins Discovery Phenotypic Services Take a human-centered unbiased approach to drug discovery: Our Phenotypic Center of Excellence features BioMAP®, Biomarker, and OncoPanel™ Services
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
MaxCyte, Inc High transfection efficiency, cell viability, scale to e10 cells - closed system. R&D thru commercial manuf. for your cell therapy & biologics needs.
Gator Bio Gator Bio Next Gen BLI: Label-free system for quantitation, kinetics, and epitope binning. Small molecules, antibodies, biomolecules, receptors.
Submit a Text Ad